Delivery Order SPE2DB24D2216-SPE2DB25FGPUF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a ceiling value of $1,711.95. This firm fixed-price delivery order is scheduled for completion by October 7, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a non-set-aside competitive procurement, reflecting AmerisourceBergen's established capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for supply of Envarsus XR 4 mg tablets (100 count) under a firm fixed price contract valued at $2,141.57. This delivery order represents a non-set-aside competitive award, with an ultimate completion date of September 3, 2025. The pharmaceutical products will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) under a firm fixed-price contract valued at $4,712.76, with completion targeted for September 10, 2025. This non-set-aside award represents a competitive procurement of pharmaceutical products to support federal healthcare needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical supplier within the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on March 18, 2025, for the supply of Envarsus XR 4 mg tablets (100 count) with a ceiling value of $1,711.95. This firm fixed-price delivery order is scheduled for completion by April 8, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made on a competitive, non-set-aside basis, reflecting AmerisourceBergen's capability to meet federal procurement standards...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) valued at $1,711.95. This competitively awarded, non-set-aside delivery order carries a firm fixed price and is scheduled for completion by October 6, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a pharmaceutical supply transaction supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,288.86. This competitively awarded, firm fixed-price delivery order is set to be completed by September 8, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a single delivery order issued under a larger contract vehicle rather than a standalone...
- The Defense Logistics Agency awarded a $13.7K delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion deadline of September 16, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,423.90 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages). This firm fixed price, non-set-aside contract is scheduled for completion by September 10, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply needs through the agency's established...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on June 20, 2025, with a ceiling value of $1,711.95. The award covers the supply of Envarsus XR 4 mg tablets in a 100-count quantity, with an ultimate completion date of July 14, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded through competitive procedures. The contract is classified...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Envarsus XR 1 mg tablets (100-count) at a ceiling value of $2,577.72. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The order is scheduled for completion by October 1, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPUFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) under a firm fixed-price contract valued at $3,423.90. This non-set-aside award is scheduled for ultimate completion by October 6, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a continuation of the company's established role as a critical pharmaceutical distributor for federal medical procurement. This award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle supplying a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs and other federal health systems worldwide. AmerisourceBergen's consistent receipt of competitively awarded, non-set-aside delivery orders demonstrates the company's capability to meet rigorous federal procurement standards for pharmaceutical products across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 9/15/25 |